Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: The IFM experience

Blood

Volumn 125, Issue 13, 2015, Pages 2095-2100

  Hebraud, Benjamin ^a,b   Magrangeas, Florence ^c,d   Cleynen, Alice ^a,b   Lauwers Cances, Valerie ^a   Chretien, Marie Lorraine ^e   Hulin, Cyrille ^f   Leleu, Xavier ^g   Yon, Edwige ^a   Marit, Gerald ^h   Karlin, Lionel ⁱ   Roussel, Murielle ^a   Stoppa, Anne Marie ^j   Belhadj, Karim ^k   Voillat, Laurent ^l   Garderet, Laurent ^m   Macro, Margaret ⁿ   Caillot, Denis ^e   Mohty, Mohamad ^m   Facon, Thierry ^g   Moreau, Philippe ^c   Attal, Michel ^a   Munshi, Nikhil ^o   Corre, Jill ^a,b   Minvielle, Stephane ^c,d   Avet Loiseau, Herve ^a,b,p   more..

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b CANCER RESEARCH CENTER OF TOULOUSE   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d Team 12   (France)

^e DIJON UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY HOSPITAL OF NANCY   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h BORDEAUX UNIVERSITY HOSPITAL   (France)

ⁱ HOSPICES CIVILS DE LYON   (France)

^j INSTITUT PAOLI CALMETTES   (France)

^k HENRI MONDOR HOSPITAL   (France)

^l Department of Infectious Diseases General Hospital   (France)

^m HÔPITAL SAINT ANTOINE   (France)

ⁿ CAEN UNIVERSITY HOSPITAL   (France)

^o HARVARD MEDICAL SCHOOL   (United States)

^p Unité de Génomique du Myélome   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 1Q; CHROMOSOME 6P; CHROMOSOME DELETION; CHROMOSOME DELETION 17P; CHROMOSOME STRUCTURE; CHROMOSOME TRANSLOCATION 4; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOSOMY; MONOSOMY 14; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TRISOMY; TRISOMY 15; CHROMOSOME 17; CHROMOSOME 4; CHROMOSOME ABERRATION; EPIDEMIOLOGY; FRANCE; GENE TRANSLOCATION; GENETICS; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 4; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC;

EID: 84925950432     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-587964     Document Type: Article

References (19)

1. Dewald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood. 1985;66(2): 380-390.
2. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995;82(1): 41-49.
3. Laï JL, Zandecki M, Mary JY, et al. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood. 1995;85(9):2490-2497.
4. Calasanz MJ, Cigudosa JC, Odero MD, et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer. 1997;18(2):84-93.
5. Smadja NV, Bastard C, Brigaudeau C, Leroux D, Fruchart C; Groupe Français de Cytogénétique Hématologique. Hypodiploidy is a major prognostic factor in multiple myeloma. Blood. 2001;98(7):2229-2238.
6. Carrasco DR, Tonon G, Huang Y, et al. Highresolution genomic profiles define distinct clinicopathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006;9(4):313-325.
7. Avet-Loiseau H, Li C, Magrangeas F, et al. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009;27(27):4585-4590.
8. Gutiérrez NC, Castellanos MV, Martín ML, et al; GEM/PETHEMA Spanish Group. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia. 2007;21(1): 143-150.
9. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with highdose therapy. Blood. 2005;106(8):2837-2840.
10. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101(11): 4569-4575.
11. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood. 2007;109(8):3489-3495.
12. Hurt EM, Wiestner A, Rosenwald A, et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell. 2004;5(2): 191-199.
13. Hanamura I, Iida S, Akano Y, et al. Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations. Jpn J Cancer Res. 2001;92(6): 638-644.
14. Avet-Loiseau H, Malard F, Campion L, et al Intergroupe Francophone du Myélome. Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? Blood. 2011;117(6):2009-2011.
15. Avet-Loiseau H, Attal M, Campion L, et al. Longterm analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30(16):1949-1952.
16. Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood. 2012;119(9):2100-2105.
17. Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J Jr. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. Blood. 2003;101(6):2374-2376.
18. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101(4):1520-1529.
19. Boyd KD, Ross FM, Walker BA, et al. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011;17:7776-7784.